Nafros (Sodium Fluoride (18f))

Sodium Fluoride, the active ingredient in Nafros, is a radiopharmaceutical presented as an injectable solution for intravenous use. It enables PET imaging of bone metabolism to detect skeletal metastases and assess bone turnover in patients with cancer. GNH USA supplies Nafros as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and clinics worldwide.

Nafros is used in diagnostic imaging of bone‑related disease processes, providing functional information on skeletal metabolism. - Skeletal metastases: enables detection of metastatic lesions in bone via PET imaging. - Bone turnover assessment: allows evaluation of metabolic activity in bone disorders. - Oncologic staging: assists in staging of cancers with potential bone involvement.

Adverse reactions may occur following intravenous administration of Nafros.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Transient flushing: brief sensation of warmth or redness. - Mild nausea: occasional upset stomach. - Headache: low‑grade headache during or after the scan.

Serious or Rare Side Effects: - Allergic reaction (anaphylaxis): severe hypersensitivity requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure post‑injection. - Radiation‑induced skin injury: localized skin changes at high cumulative doses.

Use of Nafros requires careful consideration of patient‑specific factors and handling requirements. - Pregnancy: safety not established; avoid unless essential for maternal care. - Renal impairment: consider reduced clearance and adjust imaging schedule. - Concurrent radiopharmaceuticals: avoid overlapping scans to prevent excess radiation. - Radiation exposure: limit to necessary diagnostic procedures only. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before administering Nafros.

Major Interactions (Avoid): - High‑dose iodine therapy: may interfere with fluoride uptake in bone. - Other bone‑seeking radiotracers: can cause cumulative radiation dose.

Moderate Interactions (Monitor Closely): - Chemotherapy agents affecting bone turnover: may alter imaging results. - Bisphosphonates: may modify fluoride accumulation in skeletal tissue. - Corticosteroids: may affect bone metabolism and PET signal.